ArticleMolecular diversity2026
Polyamide-66 microplastics and early-onset ischemic stroke: a systems toxicology, multi-omics, and molecular dynamics simulation analysis.
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rates of early-onset ischemic stroke (EOS) are rising even as incidence falls at older ages. Microplastics have recently been identified as a novel stroke risk factor, and among polymers detected in human arterial thrombi from ischemic stroke, polyamide-66 (PA66) microplastics show the highest detection frequency, with microplastic burden positively correlating with stroke severity. Here, using an integrative in silico framework, we integrate systems toxicology with multi-omics causal inference to map PA66-brain pathways in EOS. Target prediction for PA66 combined with curated stroke genes yielded 12 shared proteins enriched in platelet-endothelial and blood-brain barrier pathways. Brain protein-QTL two-sample Mendelian randomization (MR) identified 43 EOS-associated proteins (20 risk, 23 protective); intersecting with the 12 candidates prioritized a single overlap, EPHX2. Higher genetically proxied brain EPHX2 associated with lower EOS risk (odds ratio, OR 0.84; 95% CI 0.71-0.98), with the strongest signal for small-artery occlusion (OR 0.50; 0.26-0.96). Cell type-resolved sc-eQTL MR supported an astrocytic association (EPHX2 expression in astrocytes OR 0.925; 0.868-0.986; P = 0.016). Two-step MR implicated metabolites downstream of EPHX2-glycosyl-N-ceramide (d18:1/24:1) increased with brain EPHX2 (OR 1.205; P = 0.0073) and were inversely associated with EOS due to small-artery occlusion (OR 0.563; P = 0.049). Molecular docking placed PA66 in the canonical inhibitor pocket of soluble epoxide hydrolase, and 100-ns molecular dynamics supported a stable, pocket-bound pose. Mouse-model phenome queries for Ephx2 knockout highlighted Gene Ontology shifts in hydrolase activity, lipid metabolism and homeostasis, consistent with disrupted lipid-epoxide signaling relevant to neurovascular integrity. Single-cell RNA-seq in young-mouse stroke datasets localized Ephx2 to astrocytes and showed post-stroke downregulation. Together, these findings nominate an astrocytic EPHX2-sphingolipid axis as a plausible route by which PA66 microplastics may promote premature stroke, providing a mechanistic basis for hazard assessment and mitigation.
Indexed as
Identifiers
42530798What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.